Compare Fox Corp Class B (FOX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs ResMed Inc. — how do they compare? Fox Corp Class B trades at $57.01 (market cap $25.36B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and ResMed Inc. for 51 Days on average.
| FOX | RMD | |
|---|---|---|
Market Cap | $25.36B | $31.89B |
Volume | 886,620 | 618,314 |
Sector | Media | Health |
52-Week High | $67.76 | $277.88 |
52-Week Low | $44.39 | $182.82 |
Typical Hold Time | 75 Days | 51 Days |
Enterprise Value | $28.72B | $31.24B |
Dividend Yield | 1.02% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.98, up 0.72% today, with a bearish technical signal but strong fundamentals. Recent earnings consistently beat estimates, with Q2 2026 EPS of $1.79 surpassing the $1.44 expectation. Revenue grew to $16.30B in 2025, and net income margin expanded to 13.88%. The company maintains solid cash flow, with operating cash flow of $3.32B in 2025. A dividend of $0.29 is scheduled for payment on September 23, 2026.
The stock presents a value opportunity with a P/E of 14.85 below industry averages, supported by analyst consensus price target of $84.75 implying 51% upside. Risks include a projected net cash flow decline to -$1.1B in 2026 and bearish technical indicators. Investor sentiment is mixed amid ongoing regulatory scrutiny of acquisitions, as noted in recent news.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
